Parkinson’s disease is a chronic and progressive neurodegenerative disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Patients also experience significant non-motor symptoms including changes in cognition and mood, sleep disturbances, and autonomic dysfunction. The condition is caused by the degeneration of dopamine-producing cells of the substantia nigra. Parkinson’s disease is incurable, but non-fatal, resulting in poor quality of life and increasing disability as the disease progresses.
CONTENTS
7 OVERVIEW
7 Latest key takeaways
9 DISEASE BACKGROUND
9 Definition
9 Patient segmentation
9 Symptoms
10 Risk factors
11 Diagnosis
13 TREATMENT
13 Non-pharmacological treatment approaches
13 Pharmacological therapy
14 Key pharmacological treatment guideline recommendations
17 EPIDEMIOLOGY
17 Prevalence methodology
20 MARKETED DRUGS
29 PIPELINE DRUGS
43 KEY REGULATORY EVENTS
43 Keeping Track: CDER Ties Monthly Novel Approval Record With Nourianz Green Light
44 PROBABILITY OF SUCCESS
45 LICENSING AND ASSET ACQUISITION DEALS
45 Bayer Eyes Indications Beyond BlueRock’s Initial Focus With $240m-Plus Buyout
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
51 DRUG ASSESSMENT MODEL
53 MARKET DYNAMICS
54 FUTURE TRENDS
54 Older, genericized core therapies will continue to dominate market share
54 Targeting niche PD segments with the greatest unmet needs will be highly rewarded
56 CONSENSUS FORECASTS
62 RECENT EVENTS AND ANALYST OPINION
62 THN102 for Parkinson’s Disease (March 31, 2020)
63 Foliglurax for Parkinson’s Disease (March 27, 2020)
65 Tavapadon for Parkinson’s Disease (September 23, 2019)
66 Nourianz for Parkinson’s Disease (August 27, 2019)
68 AP-CD/LD for Parkinson’s Disease (July 22, 2019)
69 Ongentys for Parkinson’s Disease (May 5, 2019)
70 VY-AADC for Parkinson’s Disease (May 5, 2019)
72 DynaCirc for Parkinson’s Disease (May 2, 2019)
73 AXO-Lenti-PD for Parkinson’s Disease (March 11, 2019)
77 Vectorized Alpha-Synuclein Antibody Program (AbbVie/Voyager) for Parkinson’s Disease (February 22, 2019)
78 AP-CD/LD for Parkinson’s Disease (February 19, 2019)
80 Kynmobi for Parkinson’s Disease (January 29, 2019)
81 VY-AADC for Parkinson’s Disease (January 29, 2019)
82 Protein Degradation Program (Biogen/C4) for Parkinson’s Disease (January 4, 2019)
84 KEY UPCOMING EVENTS
85 UNMET NEEDS
85 Neuroprotective treatments that slow down or halt disease progression
85 Non-motor symptoms
85 Improved control of motor fluctuations/“wearing off” periods
85 New effective drug treatments with improved side-effect profiles
87 BIBLIOGRAPHY
88 Prescription information
90 APPENDIX
LIST OF FIGURES
10 Figure 1: Parkinson’s disease symptoms and symptom domains
19 Figure 2: Trends in prevalent cases of Parkinson’s disease, 2018–27
29 Figure 3: Overview of pipeline drugs for Parkinson’s disease in the US
29 Figure 4: Pipeline drugs for Parkinson’s disease, by company
30 Figure 5: Pipeline drugs for Parkinson’s disease, by drug type
30 Figure 6: Pipeline drugs for Parkinson’s disease, by classification
44 Figure 7: Probability of success in the Parkinson’s disease pipeline
46 Figure 8: Clinical trials in Parkinson’s disease
46 Figure 9: Top 10 drugs for clinical trials in Parkinson’s disease
47 Figure 10: Top 10 companies for clinical trials in Parkinson’s disease
47 Figure 11: Trial locations in Parkinson’s disease
48 Figure 12: Parkinson’s disease trials status
49 Figure 13: Parkinson’s disease trials sponsors, by phase
51 Figure 14: Datamonitor Healthcare’s drug assessment summary for Parkinson’s disease
53 Figure 15: Market dynamics in Parkinson’s disease
54 Figure 16: Future trends in Parkinson’s disease
63 Figure 17: THN102 for Parkinson’s Disease (March 31, 2020): Phase II – THN102-202
65 Figure 18: Foliglurax for Parkinson’s Disease (March 27, 2020): Phase II – AMBLED (Europe)
66 Figure 19: Tavapadon for Parkinson’s Disease (September 23, 2019): Phase II – Early Stage PD
70 Figure 20: Ongentys for Parkinson’s Disease (May 5, 2019): Phase III – BIPARK I (301; EU), Phase III – BIPARK II (302; EU)
72 Figure 21: VY-AADC for Parkinson’s Disease (May 5, 2019): Phase I – PD-1102
73 Figure 22: DynaCirc for Parkinson’s Disease (May 2, 2019): Phase III – STEADY-PD III
76 Figure 23: AXO-Lenti-PD for Parkinson’s Disease (March 11, 2019): Phase I/II – SUNRISE-PD (1 of 2)
77 Figure 24: AXO-Lenti-PD for Parkinson’s Disease (March 11, 2019): Phase I/II – SUNRISE-PD (2 of 2)
80 Figure 25: AP-CD/LD for Parkinson’s Disease (February 19, 2019): Phase II – IN18001 (vs. Sinemet)
84 Figure 26: Key upcoming events in Parkinson’s disease
LIST OF TABLES
14 Table 1: Major approved treatments for Parkinson’s disease
18 Table 2: Prevalent cases of Parkinson’s disease, 2018–27
21 Table 3: Marketed drugs for Parkinson’s disease
31 Table 4: Pipeline drugs for Parkinson’s disease
57 Table 5: Historical global sales, by drug ($m), 2015–19
60 Table 6: Forecasted global sales, by drug ($m), 2020–24
62 Table 7: THN102 for Parkinson’s Disease (March 31, 2020)
64 Table 8: Foliglurax for Parkinson’s Disease (March 27, 2020)
65 Table 9: Tavapadon for Parkinson’s Disease (September 23, 2019)
67 Table 10: Nourianz for Parkinson’s Disease (August 27, 2019)
68 Table 11: AP-CD/LD for Parkinson’s Disease (July 22, 2019)
69 Table 12: Ongentys for Parkinson’s Disease (May 5, 2019)
71 Table 13: VY-AADC for Parkinson’s Disease (May 5, 2019)
72 Table 14: DynaCirc for Parkinson’s Disease (May 2, 2019)
74 Table 15: AXO-Lenti-PD for Parkinson’s Disease (March 11, 2019)
77 Table 16: Vectorized Alpha-Synuclein Antibody Program (AbbVie/Voyager) for Parkinson’s Disease (February 22, 2019)
79 Table 17: AP-CD/LD for Parkinson’s Disease (February 19, 2019)
80 Table 18: Kynmobi for Parkinson’s Disease (January 29, 2019)
82 Table 19: VY-AADC for Parkinson’s Disease (January 29, 2019)
83 Table 20: Protein Degradation Program (Biogen/C4) for Parkinson’s Disease (January 4, 2019)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!